Salud financiera de hoja de balance de MaxCyte

Salud financiera controles de criterios 6/6

MaxCyte tiene un patrimonio de los accionistas total de $232.2M y una deuda total de $0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son $268.3M y $36.1M respectivamente.

Información clave

Ratio deuda-patrimonio

US$0

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	US$168.29m
Patrimonio	US$232.17m
Total pasivo	US$36.11m
Activos totales	US$268.27m

Actualizaciones recientes sobre salud financiera

Recent updates

Downgrade: Here's How Analysts See MaxCyte, Inc. (LON:MXCT) Performing In The Near Term

Mar 14

Here's Why We're Not Too Worried About MaxCyte's (LON:MXCT) Cash Burn Situation

Mar 07

Analysts Have Just Cut Their MaxCyte, Inc. (LON:MXCT) Revenue Estimates By 22%

Oct 07

Here's Why We're Not Too Worried About MaxCyte's (LON:MXCT) Cash Burn Situation

Aug 12

MaxCyte, Inc. (LON:MXCT) Analysts Just Slashed This Year's Revenue Estimates By 11%

May 15

Investors Don't See Light At End Of MaxCyte, Inc.'s (LON:MXCT) Tunnel And Push Stock Down 28%

May 14

We Think MaxCyte (LON:MXCT) Can Afford To Drive Business Growth

Apr 27

Companies Like MaxCyte (LON:MXCT) Are In A Position To Invest In Growth

Nov 20

Here's Why We're Not Too Worried About MaxCyte's (LON:MXCT) Cash Burn Situation

Mar 02

We Think MaxCyte (LON:MXCT) Can Afford To Drive Business Growth

Nov 17

We're Not Worried About MaxCyte's (LON:MXCT) Cash Burn

Jul 25

MaxCyte (LON:MXCT) Shareholders Have Enjoyed A Whopping 545% Share Price Gain

Feb 22

If You Had Bought MaxCyte (LON:MXCT) Shares A Year Ago You'd Have Earned 249% Returns

Nov 24

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo ($190.2M) de MXCT superan a sus pasivos a corto plazo ($17.9M).

Pasivo a largo plazo: Los activos a corto plazo de MXCT ($190.2M) superan a sus pasivos a largo plazo ($18.3M).

Historial y análisis de deuda-patrimonio

Nivel de deuda: MXCT está libre de deudas.

Reducción de la deuda: MXCT no tiene deuda en comparación con hace 5 años, cuando su ratio deuda-patrimonio era de 41.2%.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: MXCT tiene suficiente cash runway para más de 3 años basándose en su flujo de caja libre actual.

Pronóstico de cash runway: MXCT dispone de suficiente cash runway para 2.7 años si el flujo de caja libre sigue reduciéndose a tasas históricas de 22.7% cada año.

Descubre empresas con salud financiera

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Salud financiera de hoja de balance de MaxCyte

Salud financiera controles de criterios 6/6

Información clave

Actualizaciones recientes sobre salud financiera

Here's Why We're Not Too Worried About MaxCyte's (LON:MXCT) Cash Burn Situation

Here's Why We're Not Too Worried About MaxCyte's (LON:MXCT) Cash Burn Situation

We Think MaxCyte (LON:MXCT) Can Afford To Drive Business Growth

Companies Like MaxCyte (LON:MXCT) Are In A Position To Invest In Growth

Here's Why We're Not Too Worried About MaxCyte's (LON:MXCT) Cash Burn Situation

We Think MaxCyte (LON:MXCT) Can Afford To Drive Business Growth

Recent updates

MaxCyte, Inc., Annual General Meeting, Jun 11, 2024

MaxCyte, Inc. to Report Q1, 2024 Results on May 07, 2024

Consensus revenue estimates fall by 13%

MaxCyte, Inc. Reiterates Earnings Guidance for the Year 2024

Downgrade: Here's How Analysts See MaxCyte, Inc. (LON:MXCT) Performing In The Near Term

Full year 2023 earnings: EPS and revenues exceed analyst expectations

MaxCyte, Inc. Provides Revenue Guidance for the Fiscal Year 2023 and 2024

Here's Why We're Not Too Worried About MaxCyte's (LON:MXCT) Cash Burn Situation

MaxCyte, Inc. to Report Fiscal Year 2023 Results on Mar 12, 2024

MaxCyte, Inc. Announces Departure of Cenk Sumen as Chief Scientific Officer

MaxCyte, Inc. Provides Preliminary Financial Guidance for the Fourth Quarter and Full Year Ended December 31, 2023

MaxCyte, Inc. Provides Revenue Guidance Update for 2023

Founder exercised options and sold UK£100k worth of stock

Independent Non-Executive Director notifies of intention to sell stock

New major risk - Revenue and earnings growth

MaxCyte, Inc. Provides Revenue Guidance for the Year 2023

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

New minor risk - Share price stability

MaxCyte, Inc. Provides Revenue Guidance for the Third Quarter and Full Year of 2023

Analysts Have Just Cut Their MaxCyte, Inc. (LON:MXCT) Revenue Estimates By 22%

Consensus revenue estimates fall by 22%

MaxCyte, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Maxcyte, Inc. Appoints Ali Soleymannezhad as Executive Vice President of Bioprocessing

New major risk - Revenue and earnings growth

Here's Why We're Not Too Worried About MaxCyte's (LON:MXCT) Cash Burn Situation

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

MaxCyte, Inc. Provides Revenue Guidance for the Year 2023

MaxCyte, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Founder notifies of intention to sell stock

Independent Non-Executive Director notifies of intention to sell stock

Founder exercised options and sold UK£173k worth of stock

Consensus revenue estimates fall by 11%

MaxCyte, Inc. (LON:MXCT) Analysts Just Slashed This Year's Revenue Estimates By 11%

Investors Don't See Light At End Of MaxCyte, Inc.'s (LON:MXCT) Tunnel And Push Stock Down 28%

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

MaxCyte, Inc. Provides Revenue Guidance for the Year 2023

We Think MaxCyte (LON:MXCT) Can Afford To Drive Business Growth

High number of new directors

Key Executive recently bought UK£280k worth of stock

Full year 2022 earnings released: US$0.23 loss per share (vs US$0.21 loss in FY 2021)

Founder exercised options and sold UK£139k worth of stock

MaxCyte, Inc. to Report Q4, 2022 Results on Mar 15, 2023

Founder exercised options and sold UK£127k worth of stock

Insider exercised options and sold UK£113k worth of stock

MaxCyte, Inc. Appoints Patrick J. Balthrop, Sr. as Class II Director and Member of Nominating Committee and Corporate Governance Committee

Companies Like MaxCyte (LON:MXCT) Are In A Position To Invest In Growth

Consensus forecasts updated

MaxCyte, Inc. Provides Revenue Guidance for 2022

Insider exercised options and sold UK£154k worth of stock

Insider exercised options and sold UK£147k worth of stock

MaxCyte, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Consensus forecasts updated

Maxcyte, Inc. Revenue Guidance for 2022

Second quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

MaxCyte, Inc. to Report Q2, 2022 Results on Aug 10, 2022

MaxCyte, Inc.(NasdaqGS:MXCT) dropped from Russell 2000 Growth Index

MaxCyte, Inc., Annual General Meeting, Jun 29, 2022

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

MaxCyte, Inc. Provides Revenue Guidance for the Full Year 2022

MaxCyte, Inc. to Report Q1, 2022 Results on May 09, 2022

Maxcyte, Inc. Announces CFO Changes, Effective as of April 15, 2022

Consensus estimates of losses per share improve by 16%

Here's Why We're Not Too Worried About MaxCyte's (LON:MXCT) Cash Burn Situation

MaxCyte, Inc. to Report Q4, 2021 Results on Mar 22, 2022

Maxcyte, Inc. Provides Preliminary Earnings Guidance for the Fourth Quarter and Full Year Ended December 31, 2021

Independent Chairman of the Board recently bought UK£166k worth of stock

We Think MaxCyte (LON:MXCT) Can Afford To Drive Business Growth

Founder exercised options and sold UK£1.8m worth of stock

Founder recently sold UK£944k worth of stock